This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Krishnan, B. Articles by Morgan, G. J. Search for Related Content PubMed PubMed Citation Articles by Krishnan, B. Articles by Morgan, G. J.

Non-Hodgkin Lymphoma Secondary to Cancer Chemotherapy

Institute of Cancer Research, Sutton, Surrey, SM2 5NG, United Kingdom

Requests for reprints: Gareth J. Morgan, Section of Hemato-Oncology, Institute of Cancer Research, Sutton, Surrey, SM2 5NG, United Kingdom. E-mail: gareth.morgan{at}icr.ac.uk

Increased long-term survival seen in patients with solid and hematologic cancers achieved as a result of aggressive chemoradiotherapy has come at a price. Therapy-related acute myeloid leukemia has been frequently documented in these patient cohorts, and its biology well studied. Recognition of secondary non-Hodgkin lymphoma as a cause of significant morbidity and mortality in these patients is equally important. The patterns of incidence and latency of secondary lymphomas is distinct from that of myeloid malignancies and other solid cancers. We have systematically analyzed and summarized reports from various groups over the last three decades. Risk of secondary lymphomas increases after the first 5 years of completion of chemotherapy or radiotherapy and persists for more than three decades. This reinforces the need for long-term follow-up of all patients exposed to chemoradiotherapy and confirms that chemotherapeutic agents can cause lymphoma. (Cancer Epidemiol Biomarkers Prev 2007;16(3):377–80)